On September 1, 2022, Edward T. Mathers notified the board of directors of Mirum Pharmaceuticals, Inc. of his resignation as a director of the Company and as a member of the Compensation Committee of the Board, effective September 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.76 USD | +0.86% | -3.99% | -16.12% |
10/05 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
08/05 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.12% | 115.71Cr | |
+54.05% | 6.39TCr | |
-2.02% | 4.18TCr | |
+40.01% | 4.05TCr | |
-10.22% | 2.72TCr | |
+13.42% | 2.65TCr | |
-21.60% | 1.87TCr | |
+2.89% | 1.27TCr | |
+22.40% | 1.21TCr | |
+27.49% | 1.21TCr |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals, Inc. Announces Resignation of Edward T. Mathers as A Member of the Compensation Committee of the Board, Effective September 1, 2022